Recently Featured

Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration

October 6, 2026
A novel genome engineering method, known as prime assembly, is set to revolutionize genome editing by enabling the precise integration of long DNA fragments at targeted locations within living cells. This advancement addresses the limitations of current genome editing techniques, which often rely on untargeted gene delivery and short DNA edits tailored to individual patients.…

FDA’s Center for Drug Evaluation and Research Releases Updated Organization Chart

October 5, 2026
The FDA has published an updated organization chart for its Center for Drug Evaluation and Research (CDER), outlining key leadership roles within the agency. This comprehensive chart is crucial for industry stakeholders as it delineates the structure of CDER, which plays a vital role in the regulation of pharmaceuticals in the United States. Understanding the…

Sling ropes in $123m for oral thyroid eye disease drug

October 5, 2026
Sling has secured $123 million in funding to accelerate the development of its oral thyroid eye disease drug, positioning itself as a potential competitor to Amgen’s Tepezza, the current market leader. This significant investment underscores the growing interest in innovative treatments for thyroid eye disease, a condition that affects many patients and has seen limited…

AZ, Daiichi’s Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

October 5, 2026
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu has received a positive cost-effectiveness assessment from the National Institute for Health and Care Excellence (NICE) for use in treating HER2-low advanced breast cancer. This decision comes after a previous rejection in 2024, marking a significant turnaround for the drug’s market access in England and Wales. The NICE…

Ongoing Cases